TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24505906
Drug: Local periprostatic
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local periprostatic anesthesia with 10 ml of lidocaine
Study: 12955409
Drug: Intracoronary adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary adenosine doses >16 microg
Study: 2402051
Drug: Formula without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formula without supplements
Study: 30940201
Drug: Postoperative analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative analgesics use
Study: 28335624
Drug: Cognitive-Behavioral Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-Behavioral Therapy (CBT) - 16 sessions of 50 minutes each
Study: 28335624
Drug: Escitalopram -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram - 10-20 mg/day for 12 weeks
Study: 28335624
Drug: Duloxetine -
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine - 30-60 mg/day for 12 weeks
Study: 26250060
Drug: Systemic amoxicillin
Normalized name: Amoxicillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic amoxicillin 500 mg plus metronidazole 400 mg (3x/day, 7 days)
Study: 21707564
Drug: Patient-controlled analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled analgesia using remifentanil (25-30 μg per bolus)
Study: 21707564
Drug: Intramuscular pethidine
Normalized name: pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intramuscular pethidine (50-75 mg)
Study: 16439428
Drug: Allopurinol (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (acute administration)
Study: 2851654
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of low sodium intake and enalapril
Study: 31621255
Drug: Wrist-ankle needle
Normalized name: Bos taurus ankle joint preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wrist-ankle needle combined with opioid drugs
Study: 28489798
Drug: Functional microarray
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functional microarray of microneedles plus topical 0.5% tranexamic acid solution
Study: 28489798
Drug: Sham device
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham device plus topical 0.5% tranexamic acid solution
Study: 24495682
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection group, administered via bilateral forearm intradermal injections for immunotherapy once every 21 days, measured after 2, 3, 4, and 5 times of injections.
Study: 24495682
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection group, administered via subcutaneous injection once every 21 days, measured after 3 times.
Study: 24495682
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups after blocking antibody turning positive.
Study: 19205272
Drug: Vaginal misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal misoprostol (400 microg initial dose followed by up to 1200 microg if needed)
Study: 19205272
Drug: Oral misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral misoprostol (400 microg initial dose followed by up to 1200 microg if needed)
Study: 1433118
Drug: Ceftazidime (CAZ)
Normalized name: Ceftazidime
DrugBank: Ceftazidime (DB00438)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ceftazidime (CAZ) monotherapy
Study: 1433118
Drug: Aminoglycoside+(ureido)penicillin combination
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aminoglycoside+(ureido)penicillin combination (AG+PEN)
Study: 25305763
Drug: Pulsed Dye
Normalized name: amaranth dye
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed Dye Laser (PDL) plus topical propranolol
Study: 11932272
Drug: Micronized E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized E2 (2 mg/d) plus standard-dose alendronate (10 mg/d)
Study: 11932272
Drug: Micronized E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized E2 plus low-dose alendronate (5 mg/d)
Study: 11932272
Drug: Micronized E2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micronized E2 plus placebo (one tablet per day)
Study: 10374427
Drug: HpPro 7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HpPro 7.5 mg orally three times daily
Study: 10374427
Drug: Mixture of
Normalized name: OCTADECANOL (MIXTURE OF ISOMERS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixture of known drugs (control)
Study: 50681
Drug: Placental gamma-globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental gamma-globulin administered at a dose of 3 ml
Study: 22496329
Drug: OC000459 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: OC000459 (200 mg twice daily)
Study: 16882708
Drug: 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 intravenously daily for 5 days
Study: 16882708
Drug: 20 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg/m2 subcutaneously daily for 5 days
Study: 16882708
Drug: 10 mg/m2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/m2 intravenously daily for 10 days
Study: 16882708
Drug: 5-day intravenous
Normalized name: ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-day intravenous schedule
Study: 9449019
Drug: Alcohol 0.45
Normalized name: ALCOHOL 0.45 mL in 1 mL TOPICAL LIQUID [Decolorized Iodine]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.45 g/lbw
Study: 9449019
Drug: Alcohol 0.15
Normalized name: benzyl alcohol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.15 g/lbw
Study: 9449019
Drug: Alcohol 0.30
Normalized name: ALCOHOL 0.30 mL in 1 mL TOPICAL LIQUID [Health and Beyond Green]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alcohol 0.30 g/lbw
Study: 11549204
Drug: Imidapril 10
Normalized name: imidapril 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 10 mg
Study: 8198936
Drug: Imidapril 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 40 mg
Study: 8198936
Drug: Imidapril 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril 2.5 mg
Study: 3122546
Drug: Propranolol (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (up to 320 mg per day)
Study: 3122546
Drug: Nifedipine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (up to 120 mg per day)
Study: 3122546
Drug: Sublingual nitroglycerin
Normalized name: nitroglycerin Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual nitroglycerin therapy (control)
Study: 24705022
Drug: ALICE app
Normalized name: Eyes Alive Lubricating
DrugBank: Carboxymethylcellulose (DB11059)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALICE app for patients with initially higher rate of medication errors
Study: 24705022
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (oral and written information on safe medication use)
Study: 22579007
Drug: AMC/DCBA +
Approvals — FDA: no, EMA: no, PMDA: no
Description: AMC/DCBA + lidocaine lozenge
Study: 22579007
Drug: Hexylresorcinol lozenge
Normalized name: Hexylresorcinol Lozenges
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hexylresorcinol lozenge
Study: 18932286
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine (TCM) therapy combined with Western medicine
Study: 16211732
Drug: succinylcholine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 1.0 mg kg[‐1]
Study: 16211732
Drug: rocuronium 0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: rocuronium 0.6 mg kg[‐1]
Study: 10818662
Drug: Treatment of
Normalized name: DRUGS FOR TREATMENT OF LEPRA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment of male partners of women with bacterial vaginosis
Study: 24664539
Drug: Topical lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical lidocaine (4%) pretreatment
Study: 24664539
Drug: Oral tramadol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tramadol (50-mg) pretreatment
Study: 19072827
Drug: HCV796 (a
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV796 (a selective nonstructural protein 5B polymerase inhibitor)
Study: 19072827
Drug: HCV796 monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV796 monotherapy
Study: 19072827
Drug: HCV796 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV796 in combination with interferon (30 mg/kg three times per day)
Study: 19072827
Drug: HCV796 in
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV796 in combination with pegylated interferon and ribavirin
Study: 17393073
Drug: Triapine® (96
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triapine® (96 mg/m2 2‐h infusion daily for 4 days, repeated every 2 weeks)
Study: 12825566
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg oxycodone
Study: 8634808
Drug: 10% glycolic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10% glycolic acid-based moisturizer (twice daily)
Study: 1626678
Drug: Topical anaesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical anaesthesia with oxybuprocaine 0.4%
Study: 6196841
Drug: Cefotaxime (Claforan)
Normalized name: cefotaxime Injection [Claforan]
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime (Claforan) given peroperatively and daily for five days
Study: 6196841
Drug: Methenamine (Hiprex)
Normalized name: Methenamine
DrugBank: Methenamine (DB06799)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methenamine (Hiprex) given daily from the day before the operation for a total of six days
Study: 30318332
Drug: Placebo (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (5 mL normal saline)
Study: 31117092
Drug: Biological graft
Normalized name: polyvinyl alcohol graft polyethylene glycol copolymer (3:1; 45000 MW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological graft
Study: 22906114
Drug: Early orthodontic
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early orthodontic treatment (initial maxillary expansion and subsequent activator therapy)
Study: 22906114
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no early orthodontic treatment)
Study: 12394122
Drug: Radioactive iodine
Normalized name: Iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Radioactive iodine treatment (I-131)
Study: 9920085
Drug: Testosterone enanthate
Normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Testosterone enanthate (200 mg/week)
Study: 7755384
Drug: AO-90 (500-750
Approvals — FDA: no, EMA: no, PMDA: no
Description: AO-90 (500-750 mL/day)
Study: 7755383
Drug: C/MF (Amiparen,
Approvals — FDA: no, EMA: no, PMDA: no
Description: C/MF (Amiparen, 600-800 mL/day)
Study: 30772866
Drug: Topical intranasal
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical intranasal tranexamic acid (TXA)
Study: 27995674
Drug: Cognitive Analytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Analytic Therapy (CAT), 24 sessions
Study: 21178181
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (0.052 µg•kg of BW(‐1)•d(‐1))
Study: 21178181
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (0.103 µg•kg of BW(‐1)•d(‐1))
Study: 21178181
Drug: GLP-1 infusion
Normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 infusion (0.155 µg•kg of BW(‐1)•d(‐1))
Study: 21178181
Drug: CCK infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK infusion (0.069 µg•kg of BW(‐1)•d(‐1))
Study: 21178181
Drug: CCK infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK infusion (0.138 µg•kg of BW(‐1)•d(‐1))
Study: 21178181
Drug: CCK infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK infusion (0.207 µg•kg of BW(‐1)•d(‐1))
Study: 21178181
Drug: CCK infusion
Normalized name: CCK-8
DrugBank: Sincalide (DB09142)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CCK infusion
Study: 18515460
Drug: Aripiprazole (5-15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aripiprazole (5-15 mg)
Study: 7774313
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg metaproterenol aerosol pretreatment
Study: 7774313
Drug: No bronchodilator
Approvals — FDA: no, EMA: no, PMDA: no
Description: No bronchodilator
Study: 3291110
Drug: Ribomunyl aerosol
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ribomunyl aerosol and injections (n = 17)
Study: 30633776
Drug: 2012 RCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2012 RCT preparation costs
Study: 30633776
Drug: 2016 RCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2016 RCT preparation costs
Study: 29231500
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride sustained-release capsules, 0.2 mg, once a day for 6 weeks.
Study: 26619557
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg desloratadine tablets
Study: 18071677
Drug: CCKb receptor
Normalized name: Toll-like receptor 9
DrugBank: Toll-like receptor 9 (DB15320)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCKb receptor agonist pentagastrin (0.1 microg/kg)
Study: 18071677
Drug: mu-opioid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: mu-opioid receptor agonist remifentanil (0.0625 microg/kg)
Study: 14587169
Drug: Oral glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycoprotein IIb/IIIa receptor antagonists
Study: 15239621
Drug: Sirolimus (target
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sirolimus (target trough level 10-15 ng/mL)
Study: 8573755
Drug: Intensified care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified care (IC) - hypertension teaching and treatment program based on blood pressure self-monitoring
Study: 8573755
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (RC) - routine antihypertensive therapy
Study: 2232966
Drug: Combined chemo-immunotherapy
Normalized name: Chem-Star Recover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined chemo-immunotherapy with thymopentin
Study: 2232966
Drug: Only chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Only chemotherapy
Study: 326097
Drug: Pyridinolcarbamate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridinolcarbamate (1.5 g thrice daily for 4 weeks)
Study: 326097
Drug: Inositol niacinate
Normalized name: Inositol niacinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol niacinate (1.2 g thrice daily for 4 weeks)
Study: 326097
Drug: Pyridinolcarbamate (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridinolcarbamate (1.5 g thrice daily for 6 weeks)
Study: 326097
Drug: Inositol niacinate
Normalized name: Inositol niacinate
DrugBank: Inositol nicotinate (DB08949)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inositol niacinate (1.2 g thrice daily for 6 weeks)
Study: 25997115
Drug: PF-04958242 (0.27
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04958242 (0.27 mg)
Study: 25997115
Drug: PF-04958242 (0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-04958242 (0.35 mg)
Study: 7527107
Drug: Trandolapril 2
Normalized name: trandolapril 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 2 mg/day
Study: 7527107
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of trandolapril 2 mg/day and HCTZ 25 mg/day
Study: 2501093
Drug: GTN patch
Normalized name: GTN
Approvals — FDA: no, EMA: no, PMDA: no
Description: GTN patch (7.5 mg GTN (24h)‐1)
Study: 19199105
Drug: Standard decongestive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard decongestive lymphatic therapy (DLT) with pneumatic compression (PC) (bandage group, N = 21)
Study: 1636712
Drug: Intravenous saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous saline (control)
Study: 7871360
Drug: Miconazole 55
Normalized name: Miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Miconazole 55 mg/g denture lacquer applied once on the mucosal denture surface
Study: 31072195
Drug: L-shaped silicone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-shaped silicone prosthesis (group A)
Study: 28350759
Drug: Trans-resveratrol (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trans-resveratrol (75 mg, twice daily)
Study: 24353564
Drug: Mat Pilates
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mat Pilates exercise program (8 weeks, 3 times weekly)
Study: 21685641
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality exposure therapy (VRET)
Study: 18544984
Drug: Bicalutamide 150
Normalized name: bicalutamide 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicalutamide 150 mg
Study: 9797850
Drug: CRH administration
Normalized name: Ovine CRH
DrugBank: Corticorelin ovine triflutate (DB09067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRH administration (100 micrograms hCRH)
Study: 7658052
Drug: maintenance therapy
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: maintenance therapy
Study: 2732449
Drug: Recombinant interferon‐alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant interferon‐alpha (rIFN alpha)‐2A, administered intramuscularly in doses ranging from 1.5 MU to 20 MU/m2 of body surface, two or three times weekly during 4‐6 months.
Study: 22298121
Drug: Riluzole (100-200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Riluzole (100-200 mg/day)
Study: 18983318
Drug: Immediate restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate restoration of single implants placed at the time of tooth extraction (test group)
Study: 18983318
Drug: Immediate restoration
Normalized name: DRESSING,RESTORE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate restoration of single implants placed 8 weeks after tooth extraction (control group)
Study: 16098300
Drug: Glycoprotein IIb/IIIa
Normalized name: GLYCOPROTEIN IIB/IIIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glycoprotein IIb/IIIa inhibitors during TAXUS stent implantation
Study: 16098300
Drug: Control stent
Normalized name: castor fiber scent gland secretion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control stent without GP IIb/IIIa inhibitors
Study: 8934156
Drug: Urea-gel method
Normalized name: urea Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea-gel method
Study: 6384289
Drug: 5% topical
Normalized name: BP 5% Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% topical minoxidil for 12 months
Study: 6384289
Drug: 1% topical
Normalized name: SSD 1% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% topical minoxidil for 12 months
Study: 31129108
Drug: Subjective sleep
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjective sleep parameters (PSQI-sleep medication)
Study: 24742124
Drug: Metformin (M)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin (M) 2 g/d
Study: 24742124
Drug: Metformin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin + Oral Contraceptive Pills (M+OCP)
Study: 22883485
Drug: cART containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: cART containing Tenofovir and a non-nucleoside reverse-transcriptase-inhibitor (TFV/NNRTI)
Study: 22883485
Drug: cART containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: cART containing Tenofovir and a protease-inhibitor (TFV/PI)
Study: 11744653
Drug: Sublingual cyclodextrin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual cyclodextrin androstenediol (Sl Diol) 20 mg
Study: 8547937
Drug: Feeding 2
Normalized name: TUBE FEEDING 24FR Y-PORT AMT#4-2402
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feeding 2 (69 g CHO/400 ml)
Study: 6342168
Drug: Saline (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (1 ml)
Study: 6412271
Drug: Sulpiride morning
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride morning only dose
Study: 6412271
Drug: Sulpiride daily
Normalized name: sulpiride
DrugBank: Sulpiride (DB00391)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulpiride daily total dose in two equal fractions at 8 a.m. and 4 p.m.
Study: 29061504
Drug: S‐1 therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: S‐1 therapy
Study: 21562067
Drug: saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 2.5 mg + glyburide 7.5 mg
Study: 21562067
Drug: saxagliptin 5
Normalized name: sAXagliptin 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 5 mg + glyburide 7.5 mg
Study: 21562067
Drug: saxagliptin 2.5
Normalized name: sAXagliptin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: saxagliptin 2.5 mg
Study: 16549457
Drug: L-[1-(13C)]leucine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[1-(13C)]leucine at 65 mg/(kg.d)
Study: 16549457
Drug: L-[1-(13C)]leucine at
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[1-(13C)]leucine at 45 mg/(kg.d)
Study: 16549457
Drug: L-[1-(13C)]lysine (control)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-[1-(13C)]lysine (control)
Study: 10681363
Drug: Delavirdine (DLV)
DrugBank: Delavirdine (DB00705)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Delavirdine (DLV) monotherapy
Study: 9196609
Drug: Dexfenfluramine (dF)
Normalized name: dexfenfluramine
DrugBank: Dexfenfluramine (DB01191)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexfenfluramine (dF) 15 mg twice daily for 7 days